鎌状赤血球症治療市場レポート：治療タイプ、エンドユーザー、地域別、2024～2032年

世界の鎌状赤血球症治療市場規模は2023年に35億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに119億米ドルに達し、2024～2032年の間に14％の成長率（CAGR）を示すと予測しています。

鎌状赤血球症（SCD）は、全身に酸素を運ぶタンパク質であるヘモグロビンに影響を及ぼす遺伝的な赤血球（RBC）障害です。急性胸部症候群、貧血、血管閉塞性クリーゼ（VOC）など多くの合併症を引き起こします。現在、SCDの治療には血液移植と骨髄移植が一般的に行われています。この移植は、罹患した骨髄をドナーからの健康な骨髄と置き換えるものです。薬剤療法や輸血などの他の効果的な治療法も、特定の症状を軽減し、患者を延命させることができるため、利用されています。

SCDに罹患する患者数が大幅に増加していることは、SCDを効果的に治療できる新薬の需要に影響を与える重要な要因の一つです。その結果、各国の医療規制当局は新しい治療法の早期承認に力を入れています。例えば、米国食品医薬品局（USFDA）は2019年、SCDの成人と小児が経験する痛みを軽減する新薬を承認しました。さらに、政府当局は研究開発（R&D）活動を支援し、研究者や製薬会社に新規治療法の開発を促しています。例えば、米国国立心肺血液研究所（NHLBI）の研究者は、細胞の機能を改善するために、欠損した遺伝子を回復させたり、新しいDNA株を追加したりする遺伝子治療に取り組んでいます。こうした技術革新は、可処分所得の増加や利用可能な医療サービスに対する個人の意識の高まりとともに、市場成長に寄与すると予想されます。

本レポートで扱う主要質問

• 2023年の世界の鎌状赤血球症治療市場の市場規模は？
• 2024～2032年の世界の鎌状赤血球症治療市場の予想成長率は？
• 世界の鎌状赤血球症治療市場に対するCOVID-19の影響は？
• 世界の鎌状赤血球症治療市場を牽引する主要因は何か？
• 鎌状赤血球症治療市場の世界市場における治療タイプ別内訳は？
• 世界の鎌状赤血球症治療市場のエンドユーザー別内訳は？
• 世界の鎌状赤血球症治療市場における主要地域は？
• 世界の鎌状赤血球症治療市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の鎌状赤血球症治療市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：治療タイプ別

• 輸血
• 薬剤療法
• 骨髄移植

第7章 市場内訳：エンドユーザー別

• 病院
• 診断センター
• その他

第8章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第9章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第12章 価格分析

第13章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • AstraZeneca Plc
  • Baxter International Inc.
  • bluebird bio Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics
  • Emmaus Medical Inc.
  • Global Blood Therapeutics Inc.
  • GlycoMimetics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sangamo Therapeutics

List of Figures

• Figure 1: Global: Sickle Cell Disease Treatment Market: Major Drivers and Challenges
• Figure 2: Global: Sickle Cell Disease Treatment Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Sickle Cell Disease Treatment Market: Breakup by Treatment Type (in %), 2023
• Figure 5: Global: Sickle Cell Disease Treatment Market: Breakup by End User (in %), 2023
• Figure 6: Global: Sickle Cell Disease Treatment Market: Breakup by Region (in %), 2023
• Figure 7: Global: Sickle Cell Disease Treatment (Blood Transfusion) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 8: Global: Sickle Cell Disease Treatment (Blood Transfusion) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 9: Global: Sickle Cell Disease Treatment (Pharmacotherapy) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Sickle Cell Disease Treatment (Pharmacotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Sickle Cell Disease Treatment (Bone Marrow Transplant) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Sickle Cell Disease Treatment (Bone Marrow Transplant) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Sickle Cell Disease Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Sickle Cell Disease Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Sickle Cell Disease Treatment (Diagnostic Centers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Sickle Cell Disease Treatment (Diagnostic Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: Global: Sickle Cell Disease Treatment (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: Global: Sickle Cell Disease Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: North America: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: North America: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: United States: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: United States: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: Canada: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: Canada: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: Asia-Pacific: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: Asia-Pacific: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: China: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: China: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: Japan: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: Japan: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: India: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: India: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: South Korea: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: South Korea: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: Australia: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 36: Australia: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 37: Indonesia: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 38: Indonesia: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 39: Others: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 40: Others: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 41: Europe: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 42: Europe: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 43: Germany: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 44: Germany: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 45: France: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 46: France: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 47: United Kingdom: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 48: United Kingdom: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 49: Italy: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 50: Italy: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 51: Spain: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 52: Spain: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 53: Russia: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 54: Russia: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 55: Others: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 56: Others: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 57: Latin America: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 58: Latin America: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 59: Brazil: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 60: Brazil: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 61: Mexico: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 62: Mexico: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 63: Others: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 64: Others: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 65: Middle East and Africa: Sickle Cell Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
• Figure 66: Middle East and Africa: Sickle Cell Disease Treatment Market: Breakup by Country (in %), 2023
• Figure 67: Middle East and Africa: Sickle Cell Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 68: Global: Sickle Cell Disease Treatment Industry: SWOT Analysis
• Figure 69: Global: Sickle Cell Disease Treatment Industry: Value Chain Analysis
• Figure 70: Global: Sickle Cell Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Sickle Cell Disease Treatment Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Sickle Cell Disease Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
• Table 3: Global: Sickle Cell Disease Treatment Market Forecast: Breakup by End User (in Million US$), 2024-2032
• Table 4: Global: Sickle Cell Disease Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: Sickle Cell Disease Treatment Market: Competitive Structure
• Table 6: Global: Sickle Cell Disease Treatment Market: Key Players

The global sickle cell disease treatment market size reached US$ 3.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.9 Billion by 2032, exhibiting a growth rate (CAGR) of 14% during 2024-2032.

Sickle cell disease (SCD) is a genetic red blood cell (RBC) disorder that affects hemoglobin, a protein that carries oxygen throughout the body. It leads to many complications, such as acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). At present, blood and bone marrow transplant is commonly suggested by doctors for treating SCD. It involves replacing affected bone marrow with a healthy substitute received from a donor. Other effective treatments, such as medications and blood transfusions, are also being utilized as they can reduce specific symptoms and prolong the life of patients.

A considerable increase in the number of individuals suffering from SCD represents one of the significant factors influencing the demand for new medications that can treat the condition effectively. As a result, the health regulatory authorities of numerous countries are focusing on fast-track approval of new treatment methods. For instance, the United States Food and Drug Administration (USFDA) approved a new medicine in 2019 to reduce the pain experienced by adults and children with SCD. Additionally, government authorities are supporting research and development (R&D) activities to encourage researchers and pharmaceutical companies to develop novel treatments. For instance, researchers at the National Heart, Lung, and Blood Institute (NHLBI) in the US are working on genetic therapies that can restore a missing gene or add a new DNA strain to improve the functioning of cells. These innovations, along with the rising disposable incomes and the growing awareness among individuals about the available healthcare services, are anticipated to contribute to market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global sickle cell disease treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on treatment type and end user.

Breakup by Treatment Type:

Blood Transfusion

Pharmacotherapy

Bone Marrow Transplant

Breakup by End User:

Hospitals

Diagnostic Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc. and Sangamo Therapeutics.

Key Questions Answered in This Report

• 1. What was the size of the global sickle cell disease treatment market in 2023?
• 2. What is the expected growth rate of the global sickle cell disease treatment market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global sickle cell disease treatment market?
• 4. What are the key factors driving the global sickle cell disease treatment market?
• 5. What is the breakup of the global sickle cell disease treatment market based on the treatment type?
• 6. What is the breakup of the global sickle cell disease treatment market based on the end user?
• 7. What are the key regions in the global sickle cell disease treatment market?
• 8. Who are the key players/companies in the global sickle cell disease treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Sickle Cell Disease Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Treatment Type

• 6.1 Blood Transfusion
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Pharmacotherapy
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Bone Marrow Transplant
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Diagnostic Centers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 AstraZeneca Plc
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Baxter International Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 bluebird bio Inc.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Bristol-Myers Squibb Company
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 CRISPR Therapeutics
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Emmaus Medical Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Global Blood Therapeutics Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
  • 13.3.8 GlycoMimetics Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
  • 13.3.9 Novartis AG
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Pfizer Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Sangamo Therapeutics
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis